A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：556

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/JBMR.040305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：1059 / 1066

页数：8

共 50 条

[11] Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients:: semiquantitative and quantitative analysis [J].

Crotti, TN ;

Smith, MD ;

Weedon, H ;

Ahern, MJ ;

Findlay, DM ;

Kraan, M ;

Tak, PP ;

Haynes, DR .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (12) :1047-1054

[12] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].

Croucher, PI ;

Shipman, CM ;

Lippitt, J ;

Perry, M ;

Asosingh, K ;

Hijzen, A ;

Brabbs, AC ;

van Beek, EJR ;

Holen, I ;

Skerry, TM ;

Dunstan, CR ;

Russell, GR ;

Van Camp, B ;

Vanderkerken, K .

BLOOD, 2001, 98 (13) :3534-3540

[13] Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women [J].

Eastell, R ;

Mallinak, N ;

Weiss, S ;

Ettinger, M ;

Pettinger, M ;

Cain, D ;

Flessland, K ;

Chesnut, C .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (03) :594-598

[14] Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].

Emery, JG ;

McDonnell, P ;

Burke, MB ;

Deen, KC ;

Lyn, S ;

Silverman, C ;

Dul, E ;

Appelbaum, ER ;

Eichman, C ;

DiPrinzio, R ;

Dodds, RA ;

James, IE ;

Rosenberg, M ;

Lee, JC ;

Young, PR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367

[15] NORMAL AND PATHOLOGICAL REMODELING OF HUMAN TRABECULAR BONE - 3-DIMENSIONAL RECONSTRUCTION OF THE REMODELING SEQUENCE IN NORMALS AND IN METABOLIC BONE-DISEASE [J].

ERIKSEN, EF .

ENDOCRINE REVIEWS, 1986, 7 (04) :379-408

[16] Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial [J].

Fogelman, I ;

Ribot, C ;

Smith, R ;

Ethgen, D ;

Sod, E ;

Reginster, JY .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1895-1900

[17] TETRACYCLINE-BASED HISTOLOGICAL ANALYSIS OF BONE REMODELING [J].

FROST, HM .

CALCIFIED TISSUE RESEARCH, 1969, 3 (03) :211-&

[18]

Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO

[19]

2-P

[20] Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].

Harris, ST ;

Watts, NB ;

Genant, HK ;

McKeever, CD ;

Hangartner, T ;

Keller, M ;

Chesnut, CH ;

Brown, J ;

Eriksen, EF ;

Hoseyni, MS ;

Axelrod, DW ;

Miller, PD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352

← 1 2 3 4 5 →